Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
apalutamide
castration resistance
darolutamide
enzalutamide
next generation androgen receptor inhibitors
non-metastatic setting
prostate cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
03
2020
accepted:
11
11
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.
Identifiants
pubmed: 33488778
doi: 10.1177/1758835920978134
pii: 10.1177_1758835920978134
pmc: PMC7768840
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1758835920978134Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: Pernelle Lavaud: Ipsen, Janssen, Astellas, Astra Zeneca, Mundi Pharma Clément Dumont: Ipsen ConstanceThibault: Astellas, Janssen,Pfizer, Sanofi, Ipsen, Astra Zeneca, Amgen Laurence Albiges: Pfizer, Novartis, Merck, Astra Zeneca, MSD, Roche, Ipsen, Bristol Myer Squibb, Astellas, Exeliquis, Amgen, Peloton therapeutics, Corvus Pharmaceuticals Giulia Baciarello: Amgen, Janssen Oncology, Sanofi, Roche, Europharma, Modra Pharmaceuticals, Astellas, Pharma, Astra Zeneca, Ipsen, Emeline Colomba: Ipsen, BMS GSK Pfizer Sanofi Ronan Flippot: BMS Alina Fuerea: none Yohann Loriot: Roche, Astellas, Janssen, BMS, MSD, Pfizer, Sanofi, Ipsen, Astra Zeneca, Seattle Genetics Karim Fizazi: Janssen, Astellas, Sanofi, Bayer, Astra Zeneca, Orion, Curevac, MSD, Clovis, Essa, Amgen
Références
J Clin Oncol. 2016 Jun 20;34(18):2098-106
pubmed: 26811535
Eur Urol Focus. 2018 Jul;4(4):547-553
pubmed: 28753851
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
BJU Int. 2017 Apr;119(4):550-559
pubmed: 27208546
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Eur Urol Oncol. 2019 Sep 23;:
pubmed: 31558422
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Eur Urol Oncol. 2018 Aug;1(3):238-241
pubmed: 31102627
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Clin Cancer Res. 2011 Jun 15;17(12):3876-83
pubmed: 21680543
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
Lancet Oncol. 2009 Oct;10(10):981-91
pubmed: 19796750
J Urol. 2018 Aug;200(2):344-352
pubmed: 29630978
Target Oncol. 2019 Oct;14(5):527-539
pubmed: 31571095
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Sci Rep. 2015 Jul 03;5:12007
pubmed: 26137992
Br J Clin Pharmacol. 2018 Jan;84(1):122-129
pubmed: 28881501
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
Lancet Oncol. 2019 Dec;20(12):1740-1749
pubmed: 31629656
J Med Chem. 2010 Apr 8;53(7):2779-96
pubmed: 20218717
Eur Urol. 2016 Dec;70(6):963-970
pubmed: 27160947
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
Ann Oncol. 2019 Nov 1;30(11):1813-1820
pubmed: 31560066
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2020 Jun 4;382(23):2197-2206
pubmed: 32469184
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Lancet Oncol. 2016 Jun;17(6):727-737
pubmed: 27155740
N Engl J Med. 2020 Sep 10;383(11):1040-1049
pubmed: 32905676
N Engl J Med. 2017 Feb 2;376(5):417-428
pubmed: 28146658
J Clin Oncol. 2017 Sep 20;35(27):3097-3104
pubmed: 28796587
World J Urol. 1994;12(2):99-103
pubmed: 8087144
Eur Urol Focus. 2017 Dec;3(6):606-614
pubmed: 28753849
Lancet Oncol. 2014 Aug;15(9):975-85
pubmed: 24974051
J Clin Oncol. 2005 May 1;23(13):2918-25
pubmed: 15860850
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
Eur Urol. 2018 Jan;73(1):4-8
pubmed: 28851578
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Clin Cancer Res. 2019 Dec 15;25(24):7448-7454
pubmed: 31511295
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Ann Oncol. 2015 Sep;26 Suppl 5:v69-77
pubmed: 26205393
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30
pubmed: 26733552